查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602332

基于人工智慧的临床试验市场：按组成部分、特征、阶段、技术、应用和最终用户 - 2025-2030 年全球预测

AI-based Clinical Trials Market by Component (Services, Software), Function (Adverse Event Detection, Data Collection & Analysis, Patient Recruitment & Screening), Phase, Technology, Application, End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年基于人工智慧的临床试验市场规模为65.2亿美元，预计2024年将达到77.3亿美元，复合年增长率为18.79%，预计2030年将达到217.9亿美元。

基于人工智慧的临床试验市场包括利用人工智慧技术简化临床试验流程并提高效率、准确性和速度。这包括患者招募、资料管理、监控和预测分析中的应用。这种需求源自于传统临床试验模型效率低、高成本且耗时的过程，这使得人工智慧对于寻求彻底改变药物开发的製药公司来说成为有吸引力的选择。人工智慧在临床试验中的最终用途主要是由製药公司、生物技术公司和委外研发机构(CRO) 来优化临床试验设计、缩短时间并提供对患者资料，从而改善患者的治疗结果。主要成长动力包括对个人化医疗的需求不断增长、人工智慧在医疗保健领域的日益采用以及对更高效的药物开发流程的需求。人工智慧的整合为该领域的参与者提供了巨大的机会，因为它可以显着缩短新药和治疗方法的上市时间。然而，资料隐私问题、监管障碍以及对高品质资料集集的需求等挑战可能会阻碍市场成长。为了克服这些限制，企业应该投资建立强大的资料基础设施，确保遵守监管标准，并培养与人工智慧新兴企业和技术供应商的伙伴关係。创新领域包括利用机器学习演算法进行预测分析、利用自然语言处理进行资料提取，以及利用人工智慧模型进行临床试验中基于风险的监控。透过专注于提高患者安全、简化监管合规流程并促进即时试验协调的人工智慧技术，业务成长可以大大受益。总体而言，由于人工智慧技术的进步以及对更高效、更具成本效益的临床试验解决方案的需求不断增长，市场有望实现显着增长，但持续增长需要解决根本挑战。

主要市场统计
基准年[2023] 65.2亿美元
预测年份 [2024] 77.3亿美元
预测年份 [2030] 217.9亿美元
复合年增长率（%） 18.79%

市场动态：揭示快速发展的基于人工智慧的临床试验市场的关键市场洞察

基于人工智慧的临床试验市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 需要人工智慧来帮助推动和改进临床试验
    • 越来越需要降低医疗成本和硬体成本
    • 许多製药公司越来越多地采用基于人工智慧的药物开发技术
  • 市场限制因素
    • 缺乏个人参与导致失业率上升
    • 缺陷诊断的可能性
  • 市场机会
    • 基于人工智慧的临床试验的技术进步和创新
    • 大型製药企业增加与人工智慧供应商的合资和合作关係
  • 市场挑战
    • 对引入 EHR互通性的担忧

波特五力：驾驭人工智慧临床试验市场的策略工具

波特的五力架构是了解以人工智慧为基础的临床试验市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解基于人工智慧的临床试验市场的外部影响

外部宏观环境因素在塑造基于人工智慧的临床试验市场的绩效动态方面发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解以人工智慧为基础的临床试验市场的竞争格局

基于人工智慧的临床试验市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵基于人工智慧的临床试验市场供应商的绩效评估

FPNV 定位矩阵是评估以人工智慧为基础的临床试验市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製基于人工智慧的临床试验市场的成功之路

基于人工智慧的临床试验市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 需要人工智慧来帮助加速和改进临床试验
      • 越来越需要降低医疗成本和硬体成本
      • 大多数製药公司已采用基于人工智慧的药物开发技术
    • 抑制因素
      • 缺乏个人参与导致失业率上升
      • 可能诊断错误
    • 机会
      • 基于人工智慧的临床试验的技术进步和创新
      • 大型製药公司正在扩大与人工智慧供应商的合资企业和合作伙伴关係
    • 任务
      • 对引入 EHR互通性的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章基于人工智慧的临床试验市场：按组成部分

  • 服务
  • 软体

第七章 人工智慧的临床试验市场：依功能分类

  • 不利事件检测
  • 资料收集与分析
  • 病人招募和筛检
  • 预测模型
  • 测试设计与最佳化

第八章基于人工智慧的临床试验市场分阶段

  • 第一阶段
  • 第二阶段
  • 第三阶段

第九章基于人工智慧的临床试验市场：按技术分类

  • 机器学习
  • 自然语言处理

第10章基于人工智慧的临床试验市场：按应用分类

  • 心血管疾病
  • 感染疾病
  • 代谢性疾病
  • 神经系统疾病
  • 肿瘤学

第十一章 以人工智慧为基础的临床试验市场：依最终使用者分类

  • 学术研究所
  • 合约调查机构
  • 医院
  • 製药和生物製药公司

第十二章美洲人工智慧临床试验市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太地区基于人工智慧的临床试验市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十四章 欧洲、中东和非洲人工智慧临床试验市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AiCure, LLC
  • Aiforia Technologies Oyj
  • Antidote Technologies, Inc.
  • Ardigen SA
  • Avantor, Inc.
  • BioAge Labs
  • BioSymetrics Inc.
  • Deep 6 AI Inc.
  • Envisagenics
  • Euretos Services BV
  • Exscientia PLC
  • GNS Healthcare
  • Google LLC by Alphabet Inc.
  • Innoplexus AG
  • InSilico Medicine
  • Intel Corporation
  • International Business Machines Corporation
  • Koninklijke Philips NV
  • Median Technologies
  • Nuritas Limited
  • Pharmaceutical Pipeline Enhancement Strategies, LLC
  • Saama Technologies, Inc.
  • Symplr Software LLC
  • Trials.ai, Inc. by ZS Associates, Inc.
  • Unlearn.AI, Inc.
Product Code: MRR-03559044807A

The AI-based Clinical Trials Market was valued at USD 6.52 billion in 2023, expected to reach USD 7.73 billion in 2024, and is projected to grow at a CAGR of 18.79%, to USD 21.79 billion by 2030.

The AI-based Clinical Trials market encompasses the utilization of artificial intelligence technologies to streamline the clinical trial process, enhancing efficiency, accuracy, and speed. This includes applications in patient recruitment, data management, monitoring, and predictive analytics. The necessity arises from the traditional clinical trial model's inefficiencies, high costs, and time-consuming processes, making AI an attractive alternative for pharmaceutical companies aiming to innovate drug development. AI applications in clinical trials are primarily end-used by pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) to optimize trial designs, reduce timelines, and improve patient outcomes by providing deeper insights into patient data. Key growth drivers include increasing demand for personalized medicine, the growing adoption of AI in healthcare, and the need for more efficient drug development processes. The integration of AI can significantly reduce the time to market for new drugs and therapies, presenting a major opportunity for players in this space. However, challenges such as data privacy concerns, regulatory hurdles, and the need for high-quality data sets can impede market growth. To overcome these limitations, companies should invest in building robust data infrastructures, ensuring compliance with regulatory standards, and fostering partnerships with AI startups and technology providers. Areas of innovation include leveraging machine learning algorithms for predictive analytics, natural language processing for data extraction, and AI models for risk-based monitoring in trials. For business growth, focusing on AI technologies that enhance patient safety, streamline regulatory compliance processes, and facilitate real-time trial adjustments can yield substantial benefits. Overall, the market is poised for significant growth, driven by advancements in AI technologies and increasing demand for more efficient and cost-effective clinical trial solutions, although addressing underlying challenges is crucial for sustained progress.

KEY MARKET STATISTICS
Base Year [2023] USD 6.52 billion
Estimated Year [2024] USD 7.73 billion
Forecast Year [2030] USD 21.79 billion
CAGR (%) 18.79%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving AI-based Clinical Trials Market

The AI-based Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Need for artificial Intelligence which helps in boosting and improving clinical trials
    • Rising needs to reduce healthcare costs and declining hardware costs
    • Increased adoption of AI-based drug development technology by most of the pharmaceutical companies
  • Market Restraints
    • Lack of personal involvement leading to a rise in unemployment rates
    • Possibility of a defective diagnosis
  • Market Opportunities
    • Technological advancements and innovations in AI-based clinical trials
    • Major pharmaceutical companies are ensuring more joint ventures and partnerships with AI vendors
  • Market Challenges
    • Concerns associated with the adoption of EHR interoperability

Porter's Five Forces: A Strategic Tool for Navigating the AI-based Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the AI-based Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the AI-based Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the AI-based Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the AI-based Clinical Trials Market

A detailed market share analysis in the AI-based Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the AI-based Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the AI-based Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the AI-based Clinical Trials Market

A strategic analysis of the AI-based Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the AI-based Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AiCure, LLC, Aiforia Technologies Oyj, Antidote Technologies, Inc., Ardigen S.A., Avantor, Inc., BioAge Labs, BioSymetrics Inc., Deep 6 AI Inc., Envisagenics, Euretos Services BV, Exscientia PLC, GNS Healthcare, Google LLC by Alphabet Inc., Innoplexus AG, InSilico Medicine, Intel Corporation, International Business Machines Corporation, Koninklijke Philips N.V., Median Technologies, Nuritas Limited, Pharmaceutical Pipeline Enhancement Strategies, LLC, Saama Technologies, Inc., Symplr Software LLC, Trials.ai, Inc. by ZS Associates, Inc., and Unlearn.AI, Inc..

Market Segmentation & Coverage

This research report categorizes the AI-based Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Services and Software.
  • Based on Function, market is studied across Adverse Event Detection, Data Collection & Analysis, Patient Recruitment & Screening, Predictive Modeling, and Trial Design & Optimization.
  • Based on Phase, market is studied across Phase-I, Phase-II, and Phase-III.
  • Based on Technology, market is studied across Machine Learning and Natural Language Processing.
  • Based on Application, market is studied across Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Neurological Diseases, and Oncology.
  • Based on End-user, market is studied across Academic & Research Institutes, Contract Research Organization, Hospitals, and Pharmaceutical & Biopharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Need for artificial Intelligence which helps in boosting and improving clinical trials
      • 5.1.1.2. Rising needs to reduce healthcare costs and declining hardware costs
      • 5.1.1.3. Increased adoption of AI-based drug development technology by most of the pharmaceutical companies
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of personal involvement leading to a rise in unemployment rates
      • 5.1.2.2. Possibility of a defective diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements and innovations in AI-based clinical trials
      • 5.1.3.2. Major pharmaceutical companies are ensuring more joint ventures and partnerships with AI vendors
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with the adoption of EHR interoperability
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. AI-based Clinical Trials Market, by Component

  • 6.1. Introduction
  • 6.2. Services
  • 6.3. Software

7. AI-based Clinical Trials Market, by Function

  • 7.1. Introduction
  • 7.2. Adverse Event Detection
  • 7.3. Data Collection & Analysis
  • 7.4. Patient Recruitment & Screening
  • 7.5. Predictive Modeling
  • 7.6. Trial Design & Optimization

8. AI-based Clinical Trials Market, by Phase

  • 8.1. Introduction
  • 8.2. Phase-I
  • 8.3. Phase-II
  • 8.4. Phase-III

9. AI-based Clinical Trials Market, by Technology

  • 9.1. Introduction
  • 9.2. Machine Learning
  • 9.3. Natural Language Processing

10. AI-based Clinical Trials Market, by Application

  • 10.1. Introduction
  • 10.2. Cardiovascular Diseases
  • 10.3. Infectious Diseases
  • 10.4. Metabolic Diseases
  • 10.5. Neurological Diseases
  • 10.6. Oncology

11. AI-based Clinical Trials Market, by End-user

  • 11.1. Introduction
  • 11.2. Academic & Research Institutes
  • 11.3. Contract Research Organization
  • 11.4. Hospitals
  • 11.5. Pharmaceutical & Biopharmaceutical Companies

12. Americas AI-based Clinical Trials Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific AI-based Clinical Trials Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa AI-based Clinical Trials Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AiCure, LLC
  • 2. Aiforia Technologies Oyj
  • 3. Antidote Technologies, Inc.
  • 4. Ardigen S.A.
  • 5. Avantor, Inc.
  • 6. BioAge Labs
  • 7. BioSymetrics Inc.
  • 8. Deep 6 AI Inc.
  • 9. Envisagenics
  • 10. Euretos Services BV
  • 11. Exscientia PLC
  • 12. GNS Healthcare
  • 13. Google LLC by Alphabet Inc.
  • 14. Innoplexus AG
  • 15. InSilico Medicine
  • 16. Intel Corporation
  • 17. International Business Machines Corporation
  • 18. Koninklijke Philips N.V.
  • 19. Median Technologies
  • 20. Nuritas Limited
  • 21. Pharmaceutical Pipeline Enhancement Strategies, LLC
  • 22. Saama Technologies, Inc.
  • 23. Symplr Software LLC
  • 24. Trials.ai, Inc. by ZS Associates, Inc.
  • 25. Unlearn.AI, Inc.

LIST OF FIGURES

  • FIGURE 1. AI-BASED CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. AI-BASED CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. AI-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. AI-BASED CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AI-BASED CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AI-BASED CLINICAL TRIALS MARKET DYNAMICS
  • TABLE 7. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY ADVERSE EVENT DETECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY DATA COLLECTION & ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PATIENT RECRUITMENT & SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PREDICTIVE MODELING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE-I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE-II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE-III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 284. AI-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 285. AI-BASED CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023